Organovo Holdings (Organovo Holdings) GF Score : 46/100 (As of Apr. 28, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Organovo Holdings GF Score?

Organovo Holdings has the GF Score of 46, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 4/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Organovo Holdings might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Organovo Holdings's GF Score

For the Biotechnology subindustry, Organovo Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Organovo Holdings's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Organovo Holdings's GF Score distribution charts can be found below:

* The bar in red indicates where Organovo Holdings's GF Score falls into.

Organovo Holdings (NAS:ONVO) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score	Performance Potential and All-in-One Screener Examples ⁽¹⁾
91 - 100	Highest outperformance potential
81 - 90	Good outperformance potential
71 - 80	Likely to have average performance
51 - 70	Poor future performance potential
0 - 50	Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Organovo Holdings GF Score Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Organovo Holdings (Organovo Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (NAS:ONVO) » Definitions » GF Score

Comparable Companies

Traded in Other Exchanges

4OR1:Germany

Address

11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121

Website

https://www.organovo.com

Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.

Executives

David Gobel	director	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Vaidehi Joshi	director	C/O ORGANOVO HOLDINGS, INC., 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Alison Tjosvold Milhous	director	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Adam K Stern	director	STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Thomas Hess	officer: President, CFO and PFO	366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Douglas Jay Cohen	director	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Thomas E Jurgensen	officer: General Counsel & Secretary	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Jeffrey N. Miner	officer: Chief Scientific Officer	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Chris Heberlig	officer: President and CFO	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Keith Murphy	director, officer: Executive Chairman	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Steven George Hughes	officer: Chief Medical Officer	6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Carolyn Beaver	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David Shapiro	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Presnell Sharon Collins	officer: EVP, Research & Development	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Taylor Crouch	director, officer: CEO & President	440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075